Meeting
2022 ASCO Annual Meeting
EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC).
Authors
Edward B. Garon
Ronald Reagan UCLA Medical Center, Santa Monica, CA
Edward B. Garon , Stephen V. Liu , Scott Peter Owen , Martin Reck , Joel W. Neal , David Vicente , Sabeen Fatima Mekan , Farnoush Safavi , Nelumka Fernando , Tony S. K. Mok
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05186974
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9146)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9146
Abstract #
TPS9146
Poster Bd #
127b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).
First Author: Thomas A. Hensing
Poster
2019 ASCO Annual Meeting
Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.
First Author: Rina Hui
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2022 ASCO Annual Meeting
innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors.
First Author: Xiuning Le